Please assess the completion status of the following clinical trial:

Trial Title: Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Between the ages of 6-17 at the time of study participation.~* Have a diagnosis of any malignancy that required CNS treatment such as surgery and/or irradiation and/or intrathecal chemotherapy. (Patients treated with systemic chemotherapy alone are not eligible to participate)~* Off treatment and cancer free for a minimum of 6 months.~* Have a proficiency in English.~EXCLUSION CRITERIA:~* Patients with an estimated intelligence quotient (IQ) of less than 65 (based on the Wide Range Achievement Test (WRAT-3) Reading subtest) are not eligible to continue on study.~* At least one standard deviation below the level of performance predicted by their IQ on at least 2 of the 3 WISC-III subtests.~* Diagnosed with Attention Deficit Disorder (ADD) or Attention Deficit Hyperactivity Disorder (ADHD) prior to their cancer diagnosis.~* Currently taking antidepressants, antipsychotics, or other stimulants.~* Are blind.~* Have glaucoma.~* Family history of motor and phonic tics or Tourette's syndrome.~* Have seizures not controlled by antiepileptic drugs. (Note: Patients who are not experiencing seizure activity, having been on a stable dose of an antiepileptic drug for at least 12 weeks may participate)~* Taking a monoamine oxidase (MAO) inhibitor.~* Have a history of cardiovascular disease, uncontrolled hypertension or hyperthyroidism.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1- Adderall- XR® (Type: EXPERIMENTAL): Adderall-XR® 1 10 mg/day for 3-12 weeks depending on subject's response
- Arm II Concerta® (Type: EXPERIMENTAL): Concerta ® 18 mg/day for 3-12 weeks depending on subject's response

Based on this trial design, predict the completion outcome and termination type (if applicable).